These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 19372801)

  • 1. Update on HIV-1 viral load blips.
    Nettles RE; Kieffer TL
    Curr Opin HIV AIDS; 2006 Mar; 1(2):157-61. PubMed ID: 19372801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.
    Nettles RE; Kieffer TL; Kwon P; Monie D; Han Y; Parsons T; Cofrancesco J; Gallant JE; Quinn TC; Jackson B; Flexner C; Carson K; Ray S; Persaud D; Siliciano RF
    JAMA; 2005 Feb; 293(7):817-29. PubMed ID: 15713771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 viral load blips are of limited clinical significance.
    Lee PK; Kieffer TL; Siliciano RF; Nettles RE
    J Antimicrob Chemother; 2006 May; 57(5):803-5. PubMed ID: 16533823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The distribution of viral blips observed in HIV-1 infected patients treated with combination antiretroviral therapy.
    Percus JK; Percus OE; Markowitz M; Ho DD; Di Mascio M; Perelson AS
    Bull Math Biol; 2003 Mar; 65(2):263-77. PubMed ID: 12675332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV viral load: the myth of the undetectable?
    Pillay D
    Rev Med Virol; 2002; 12(6):391-6. PubMed ID: 12410530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic characteristics of HIV-1 reservoirs.
    Kim H; Perelson AS
    Curr Opin HIV AIDS; 2006 Mar; 1(2):152-6. PubMed ID: 19372800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duration of an intermittent episode of viremia.
    Di Mascio M; Percus JK; Percus OE; Markowitz M; Ho DD; Perelson AS
    Bull Math Biol; 2005 Jul; 67(4):885-900. PubMed ID: 15893558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation and management of early virological failure.
    Sax PE
    Curr Opin HIV AIDS; 2006 Sep; 1(5):409-16. PubMed ID: 19372840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viral blips during suppressive antiretroviral treatment are associated with high baseline HIV-1 RNA levels.
    Sörstedt E; Nilsson S; Blaxhult A; Gisslén M; Flamholc L; Sönnerborg A; Yilmaz A
    BMC Infect Dis; 2016 Jun; 16():305. PubMed ID: 27329293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral blip dynamics during highly active antiretroviral therapy.
    Di Mascio M; Markowitz M; Louie M; Hogan C; Hurley A; Chung C; Ho DD; Perelson AS
    J Virol; 2003 Nov; 77(22):12165-72. PubMed ID: 14581553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy.
    Wang D; Larder B; Revell A; Montaner J; Harrigan R; De Wolf F; Lange J; Wegner S; Ruiz L; Pérez-Elías MJ; Emery S; Gatell J; D'Arminio Monforte A; Torti C; Zazzi M; Lane C
    Artif Intell Med; 2009 Sep; 47(1):63-74. PubMed ID: 19524413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased inflammation in sanctuary sites may explain viral blips in HIV infection.
    Cardozo EF; Piovoso MJ; Zurakowski R
    IET Syst Biol; 2016 Aug; 10(4):153-66. PubMed ID: 27444025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment.
    Roux P; Carrieri MP; Cohen J; Ravaux I; Poizot-Martin I; Dellamonica P; Spire B
    Clin Infect Dis; 2009 Nov; 49(9):1433-40. PubMed ID: 19807275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes for therapeutic vaccines trials.
    Taiwo B; Murphy R
    Curr Opin HIV AIDS; 2006 Nov; 1(6):502-6. PubMed ID: 19372853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variable adherence to prescribed dosing regimens for protease inhibitors: scope and outcomes.
    Blaschke TF
    Curr Opin HIV AIDS; 2008 Nov; 3(6):603-7. PubMed ID: 19373030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update on HIV-1 antiretroviral resistance.
    Plank RM; Kuritzkes DR
    Curr Opin HIV AIDS; 2006 Sep; 1(5):417-23. PubMed ID: 19372841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
    Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N
    Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trials for heavily pretreated patients: update in 2006.
    Katlama C; Ghosn J
    Curr Opin HIV AIDS; 2006 Nov; 1(6):495-501. PubMed ID: 19372852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between genotypic sensitivity score and treatment outcomes in late stage HIV disease after supervised HAART.
    Castor D; Vlahov D; Hoover DR; Berkman A; Wu YF; Zeller B; Brechtl J; Hammer SM
    J Med Virol; 2009 Aug; 81(8):1323-35. PubMed ID: 19551816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.